Abstract
In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1–4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5–8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1–4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug’s tumoricidal action on 8505C cell line.
Keywords: Apoptosis, autophagy, caspase, cisplatin, iridium(III) complexes, ruthenium(II) complexes.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes
Volume: 16 Issue: 11
Author(s): Gerd Ludwig, Marija Mojić, Mirna Bulatović, Sanja Mijatović, Danijela Maksimović-Ivanić, Dirk Steinborn and Goran N. Kaluđerović
Affiliation:
Keywords: Apoptosis, autophagy, caspase, cisplatin, iridium(III) complexes, ruthenium(II) complexes.
Abstract: In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1–4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5–8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1–4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug’s tumoricidal action on 8505C cell line.
Export Options
About this article
Cite this article as:
Ludwig Gerd, Mojić Marija, Bulatović Mirna, Mijatović Sanja, Maksimović-Ivanić Danijela, Steinborn Dirk and Kaluđerović N. Goran, Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (11) . https://dx.doi.org/10.2174/1871520615666151029100749
DOI https://dx.doi.org/10.2174/1871520615666151029100749 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histone Acetylation in Neurodevelopment
Current Pharmaceutical Design Preface [Hot Topic: Therapeutic Manipulation of the Immune System: Old and New Therapeutic Approaches (Executive Editor : Emilio Jirillo)]
Current Pharmaceutical Design CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Current Medicinal Chemistry Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology PET Tracers Based on Zirconium-89
Current Radiopharmaceuticals Specificity of Binding in Protein Kinases
Current Enzyme Inhibition Adrenomedullin-RAMP2 System in Cardiovascular Development and Homeostasis
Current Hypertension Reviews Sequence and Structural Elements in the Mechanism of Function of Rhodopsin-Like Family of G Protein-Coupled-Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Purification of Transcription Factors and Identification with Mass Spectrometry
Current Analytical Chemistry The Role of HLA Promoters in Autoimmunity
Current Pharmaceutical Design Arylpyrazoles: Heterocyclic Scaffold of Immense Therapeutic Application
Current Organic Chemistry Protein Pool Maintenance During Oxidative Stress
Current Pharmaceutical Design Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Current Diabetes Reviews Molecular Elements of Apoptosis-Regulating Pathways in Follicular Thyroid Cells: Mining for Novel Therapeutic Targets in the Treatment of Thyroid Carcinoma
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues
Current Drug Metabolism Reactive Oxygen Species, Inflammation, and Lung Diseases
Current Pharmaceutical Design Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy
Current Cancer Therapy Reviews Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry